Brokerages Set Enovis Co. (NYSE:ENOV) Price Target at $75.43

Shares of Enovis Co. (NYSE:ENOV - Get Free Report) have received an average recommendation of "Buy" from the eight analysts that are covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $75.43.

A number of equities research analysts recently commented on the company. William Blair assumed coverage on Enovis in a research report on Wednesday, January 3rd. They issued an "outperform" rating for the company. Wells Fargo & Company raised their target price on Enovis from $73.00 to $79.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. Canaccord Genuity Group raised their target price on Enovis from $73.00 to $75.00 and gave the company a "buy" rating in a research report on Friday, February 23rd. UBS Group assumed coverage on Enovis in a research report on Monday, January 22nd. They set a "buy" rating and a $75.00 target price for the company. Finally, Stephens assumed coverage on Enovis in a research report on Tuesday, February 13th. They set an "overweight" rating and a $72.00 target price for the company.

Enovis Stock Up 1.2 %

NYSE ENOV traded up $0.74 on Tuesday, reaching $62.42. The company had a trading volume of 473,506 shares, compared to its average volume of 453,438. The stock has a market capitalization of $3.42 billion, a P/E ratio of -102.33 and a beta of 1.97. The company's fifty day moving average is $60.64 and its 200 day moving average is $55.10. Enovis has a 52-week low of $43.04 and a 52-week high of $66.14. The company has a quick ratio of 1.16, a current ratio of 2.43 and a debt-to-equity ratio of 0.14.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.76 by $0.03. The business had revenue of $455.00 million during the quarter, compared to analyst estimates of $444.34 million. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. Enovis's quarterly revenue was up 11.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.72 EPS. Sell-side analysts anticipate that Enovis will post 2.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. purchased a new stake in shares of Enovis in the 3rd quarter valued at about $31,000. Fifth Third Bancorp raised its holdings in shares of Enovis by 144.6% in the 3rd quarter. Fifth Third Bancorp now owns 587 shares of the company's stock valued at $31,000 after acquiring an additional 347 shares in the last quarter. State of Wyoming raised its holdings in shares of Enovis by 59,200.0% in the 4th quarter. State of Wyoming now owns 593 shares of the company's stock valued at $32,000 after acquiring an additional 592 shares in the last quarter. KBC Group NV purchased a new stake in shares of Enovis in the 4th quarter valued at about $38,000. Finally, First Horizon Advisors Inc. raised its holdings in shares of Enovis by 902.7% in the 3rd quarter. First Horizon Advisors Inc. now owns 732 shares of the company's stock valued at $39,000 after acquiring an additional 659 shares in the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.